These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6262944)

  • 1. PGI2 inhibits ischemia-induced platelet activation and prevents myocardial damage by inhibition of catecholamine release from adrenergic nerve terminals. Evidence for cAMP as common denominator.
    Schrör K; Addicks K; Darius H; Ohlendorf R; Rösen P
    Thromb Res; 1981 Jan 1-15; 21(1-2):175-80. PubMed ID: 6262944
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostacyclin prevents ischemia-induced increase of lactate and cyclic AMP in ischemic myocardium.
    Rösen R; Rösen P; Ohlendorf R; Schrör K
    Eur J Pharmacol; 1981 Feb; 69(4):489-91. PubMed ID: 6265230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PGI2 prevents ischemia-induced alterations in cardiac catecholamines without influencing nerve-stimulation-induced catecholamine release in nonischemic conditions.
    Schrör K; Darius H; Addicks K; Köster R; Smith EF
    J Cardiovasc Pharmacol; 1982; 4(5):741-8. PubMed ID: 6182404
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostacyclin-dependent differences in TXA2 formation by platelets from normal and atherosclerotic rabbits.
    Dembińska-Kièć A; Rücker W; Schönhöfer PS
    Atherosclerosis; 1979 Jun; 33(2):217-26. PubMed ID: 224890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevation of adenosine 3',5'-monophosphate levels in 3T3 fibroblasts by arachidonic acid: evidence for mediation by prostaglandin I2.
    Claesson HE; Lindgren JA; Hammarström S
    FEBS Lett; 1977 Sep; 81(2):415-8. PubMed ID: 200482
    [No Abstract]   [Full Text] [Related]  

  • 6. Possible role of prostaglandins in the regulation of coronary blood flow.
    Schrör K
    Basic Res Cardiol; 1981; 76(3):239-49. PubMed ID: 6268056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostacyclin (PGI2) decreases the cyclic AMP level in coronary arteries.
    Schrör K; Rösen P
    Naunyn Schmiedebergs Arch Pharmacol; 1979 Jan; 306(1):101-3. PubMed ID: 218118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of dipyridamole in experimental atherosclerosis. Action on PGI2, platelet aggregation and atherosclerotic plaque formation.
    Dembińska-Kièć A; Rücker W; Schönhöfer PS
    Atherosclerosis; 1979 Jul; 33(3):315-27. PubMed ID: 226106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostacyclin (PGI2) and thromboxane A2 interaction in vivo. Regulation by aspirin and relationship with anti-thrombotic therapy.
    Korbut R; Moncada S
    Thromb Res; 1978 Sep; 13(3):489-500. PubMed ID: 369028
    [No Abstract]   [Full Text] [Related]  

  • 10. Refractoriness of platelets to prostaglandins after infusion in rabbits.
    Bertelé V; Stemerman M; Schafer A; Adelman B; Smith M; Fuhro R; Salzman E
    J Lab Clin Med; 1985 Nov; 106(5):551-61. PubMed ID: 2997353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of PGI2 on platelet aggregation induced by various stimulants.
    Ohtsu A; Hoshina K; Kurozumi S; Hashimoto Y; Noguchi T; Nicolaou KC
    Nihon Ketsueki Gakkai Zasshi; 1979 Aug; 42(4):659-66. PubMed ID: 388963
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmacology of prostacyclin].
    Imai S
    Kokyu To Junkan; 1985 Jul; 33(7):845-9. PubMed ID: 2997894
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin.
    Beretz A; Stierle A; Anton R; Cazenave JP
    Biochem Pharmacol; 1982 Nov; 31(22):3597-600. PubMed ID: 6295405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissociation of antiplatelet effects from myocardial cytoprotective activity during acute myocardial ischemia in cats by a new carbacyclin derivative (ZK 36 375).
    Schrör K; Darius H; Ohlendorf R; Matzky R; Klaus W
    J Cardiovasc Pharmacol; 1982; 4(4):554-61. PubMed ID: 6181328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of adenosine 3':5'-monophosphate and platelet aggregation on thromboxane biosynthesis in human platelets.
    Lindgren JA; Claesson HE; Kindahl H; Hammarström S
    FEBS Lett; 1979 Feb; 98(2):247-50. PubMed ID: 217731
    [No Abstract]   [Full Text] [Related]  

  • 16. The pain enhancing effect of PGI2.
    Juan H
    Agents Actions Suppl; 1979; (4):204-12. PubMed ID: 386743
    [No Abstract]   [Full Text] [Related]  

  • 17. [Metabolic significance of cyclic nucleotides in the environment for fetal growth--effects of PGI2-like substance on fetal platelet function].
    Kihira M; Matsumoto T; Morikawa F; Ito M
    Nihon Sanka Fujinka Gakkai Zasshi; 1983 May; 35(5):691-8. PubMed ID: 6306121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostacyclin modulates cholesteryl ester hydrolytic activity by its effect on cyclic adenosine monophosphate in rabbit aortic smooth muscle cells.
    Hajjar DP; Weksler BB; Falcone DJ; Hefton JM; Tack-Goldman K; Minick CR
    J Clin Invest; 1982 Sep; 70(3):479-88. PubMed ID: 6286723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of prostaglandin-mediated cyclic AMP formation in protein kinase C-dependent secretion of atrial natriuretic peptide in rat cardiomyocytes.
    Church DJ; Van der Bent V; Vallotton MB; Lang U
    Biochem J; 1994 Oct; 303 ( Pt 1)(Pt 1):217-25. PubMed ID: 7945244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A possible role of thromboxane A2 (TXA2) and prostacyclin (PGI2) in circulation.
    Gryglewski RJ; Dembínska-Kieć A; Korbut R
    Acta Biol Med Ger; 1978; 37(5-6):715-23. PubMed ID: 369254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.